HLS Therapeutics Inc
Open
$4.59
Prev. Close
$4.60
High
$4.60
Low
$4.59
Market Snapshot
$135.76M
-0.40
$55.5M
85
HLS Therapeutics, Inc. engages in commercializing pharmaceutical products. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The company is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. The company is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.
emptyResult
HLS Therapeutics, Inc. engages in commercializing pharmaceutical products. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The company is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. The company is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.
Recently from Cashu
HLS Therapeutics Secures Agreement for Vascepa to Improve Cardiovascular Care in Nova Scotia
HLS Therapeutics Secures Key Agreement to Enhance Cardiovascular Care in Nova Scotia HLS Therapeutics Inc. recently announces a pivotal Product Listing Agreement (PLA) with the province of Nova Scotia…
HLS Therapeutics Inc. Reports Earnings Growth and Reduced Losses Amid Market Challenges
HLS Therapeutics Sees Positive Earnings Growth Amidst Challenges HLS Therapeutics Inc. reports a significant development in its financial performance for the first quarter of 2025, reflecting a trend…
HLS Therapeutics Inc. Reports Q1 Earnings: Sales Up, Net Losses Down
HLS Therapeutics Inc. Shows Signs of Recovery in Q1 Earnings Report HLS Therapeutics Inc. announces its earnings for the first quarter ended March 31, 2025, revealing a modest increase in sales and a…